Evidence map›Paper›PMID 38286172›Full record

ArticleClinical immunology (Orlando, Fla.)2024

IKAROS expression drives the aberrant metabolic phenotype of macrophages in chronic HIV infection.

Cecilia Vittori, Celeste Faia, Dorota Wyczechowska, Amber Trauth, Karlie Plaisance-Bonstaff, Mary Meyaski-Schluter, Krzysztof Reiss, Francesca Peruzzi

Open access · hybridAbstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Immuno-cell metabolic changes in HIV-1 infection.Infectious diseases & immunity · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Cecilia VittoriLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Celeste FaiaLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Dorota WyczechowskaLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Amber TrauthLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Karlie Plaisance-BonstaffLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Mary Meyaski-SchluterClinical and Translational Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Krzysztof ReissLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA.
Francesca PeruzziLouisiana State University Health Sciences Center and Louisiana Cancer Research Center, New Orleans, LA 70112, USA; Louisiana State University Health Sciences Center, Department of Medicine, Louisiana Cancer Research Center; New Orleans, LA 70112, USA. Electronic address: fperuz@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · USLouisiana State University · USLouisiana Cancer Research Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Translational Genomics Core (TGC)P20GM121288 · NIGMS · LSU HEALTH SCIENCES CENTER · PI Arunava Roy · 2017 to 2026
$22.4M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetrationR41CA275433 · NCI · WAYPATH PHARMA LLC · PI REISS, KRZYSZTOF · 2022 to 2022
$225k
NCI NIH HHS R41 CA275433NIGMS NIH HHS P20 GM121288NIGMS NIH HHS P30 GM114732NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The increased risk for acquiring secondary illnesses in people living with HIV (PLWH) has been associated with immune dysfunction. We have previously found that circulating monocytes from PLWH display a trained phenotype. Here, we evaluated the metabolic profile of these cells and found increased mitochondrial respiration and glycolysis of monocyte-derived macrophages (MDMs) from PLWH. We additionally found that cART shifted the energy metabolism of MDMs from controls toward increased utilization of mitochondrial respiration. Importantly, both downregulation of IKAROS expression and inhibition of the mTOR pathway reversed the metabolic profile of MDMs from PLWH and cART-treated control-MDMs. Altogether, this study reveals a very specific metabolic adaptation of MDMs from PLWH, which involves an IKAROS/mTOR-dependent increase of mitochondrial respiration and glycolysis. We propose that this metabolic adaptation decreases the ability of these cells to respond to environmental cues by "locking" PLWH monocytes in a pro-inflammatory and activated phenotype.

Indexed as

HIV InfectionsHumansMacrophagesMonocytesPhenotypeTOR Serine-Threonine KinasesTOR Serine-Threonine KinasesCell metabolismHIVHuman monocytesIKAROS

Identifiers

PMID38286172
PMCPMC10922842
OpenAlexW4391289185

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.